Alexion Pharma (ALXN) Tops Q1 EPS by 20c, Raises FY Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $2.39, $0.20 better than the analyst estimate of $2.19. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.13 billion.

GUIDANCE:

Alexion Pharma sees FY2019 EPS of $9.25-$9.45, versus the consensus of $9.31. Alexion Pharma sees FY2019 revenue of $4.675-4.75 billion, versus the consensus of $4.75 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business